Shire PLC: Top line results of Lifitegrast in OPUS2 trial: disappointing

NEUTRAL, Fair Value 3100p vs. 3150p (+15%)

News published on December Friday 6, 2013
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities